PepGen Inc. (NASDAQ:PEPG – Free Report) – Investment analysts at Wedbush raised their Q3 2023 earnings per share estimates for shares of PepGen in a research note issued on Tuesday, August 8th. Wedbush analyst L. Chico now expects that the company will earn ($0.82) per share for the quarter, up from their prior estimate of ($0.87). The consensus estimate for PepGen’s current full-year earnings is ($3.29) per share. Wedbush also issued estimates for PepGen’s Q4 2023 earnings at ($0.89) EPS, FY2023 earnings at ($3.22) EPS, Q1 2024 earnings at ($0.98) EPS, Q2 2024 earnings at ($1.01) EPS and FY2024 earnings at ($4.07) EPS.
PepGen (NASDAQ:PEPG – Get Free Report) last issued its quarterly earnings results on Thursday, May 11th. The company reported ($0.69) EPS for the quarter, topping analysts’ consensus estimates of ($0.79) by $0.10.
Check Out Our Latest Research Report on PepGen
PepGen Trading Up 5.3 %
Shares of PepGen stock opened at $5.58 on Friday. The business’s fifty day simple moving average is $8.97 and its 200 day simple moving average is $12.73. PepGen has a 12 month low of $4.32 and a 12 month high of $20.00. The firm has a market capitalization of $132.86 million, a P/E ratio of -1.71 and a beta of 1.06.
Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the company. FMR LLC grew its position in PepGen by 19.0% in the 1st quarter. FMR LLC now owns 2,609,902 shares of the company’s stock valued at $31,919,000 after acquiring an additional 417,573 shares during the last quarter. Citadel Advisors LLC purchased a new position in PepGen during the second quarter valued at approximately $2,915,000. Millennium Management LLC purchased a new position in PepGen during the second quarter valued at approximately $2,083,000. Bank of Montreal Can purchased a new position in PepGen during the second quarter valued at approximately $2,664,000. Finally, State Street Corp purchased a new position in PepGen during the second quarter valued at approximately $906,000. Hedge funds and other institutional investors own 72.20% of the company’s stock.
Insider Activity
In related news, CEO James G. Mcarthur sold 8,419 shares of the firm’s stock in a transaction on Wednesday, June 7th. The stock was sold at an average price of $16.23, for a total value of $136,640.37. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders have sold 10,719 shares of company stock valued at $173,542 in the last ninety days. 3.97% of the stock is currently owned by company insiders.
PepGen Company Profile
PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that id in Phase I clinical trial to treat individuals with Duchenne muscular dystrophy (DMD).
Read More
- Five stocks we like better than PepGen
- How to Invest in Renewable Energy
- Investing in Coffee: 3 Great Strategies to Consider
- Stock Market Sectors: What Are They and How Many Are There?
- 5 Best Stocks to Buy in a Bear Market
- How to Invest in Semiconductors
- 3 Pharmaceutical Stocks to Buy and Hold for the Long Haul
Receive News & Ratings for PepGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PepGen and related companies with MarketBeat.com's FREE daily email newsletter.
